Investigational and not approved by the FDA. This page is educational information only. It is not medical advice and not a recommendation to use anything.

IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Orforglipron

Investigational

Oral small-molecule GLP-1 agonist

Also known as: LY-3502970, GLP-1 receptor agonist 1, Foundayo, Orforglipron (USAN), OWL833, V6G

Evidence score

69/ 100

Moderate evidence

A real evidence base, with gaps

Regulatory standing. In clinical trials, not yet approved
Limited human data. Some human data exists, not conclusive
Registered human trials. 53 registered studies on ClinicalTrials.gov, most advanced Phase 4
1 cited source. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Orforglipron (LY3502970) is an investigational, non-peptide small molecule developed by Eli Lilly that activates the GLP-1 receptor and is designed to be taken by mouth. Like other GLP-1 receptor agonists, it is thought to act on appetite, gastric emptying, and insulin release after meals.

What the evidence shows

Automatic summaryLimited human data

It has been studied in a substantial number of registered human trials, including large late-stage trials in type 2 diabetes and obesity that reported reductions in blood sugar and body weight, but it is not FDA-approved for any use. Long-term safety and outcome data are still being gathered, and the listing of a Phase 4 trial is unusual for an unapproved drug and may reflect a registry labeling quirk.

Key facts

Molecular formula

C48H48F2N10O5

Molecular weight

883 g/mol

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

53registered studies

Phase 4most advanced phase

32completed (sample)

10recruiting (sample)

A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants

Phase 1CompletedNCT06704763

A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

Phase 3RecruitingNCT07202884

A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus

Phase 1CompletedNCT05086445

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

Phase 3Active Not RecruitingNCT06972459

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

144papers referencing Orforglipron

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.

N Engl J Med2023

Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.

Lancet2023

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.

N Engl J Med2025

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.

N Engl J Med2025

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.